Requirement 1: a method for predicting the response of patients with gastrointestinal inflammation to treatment including syndrome B7 antagonists, including: obtaining biological samples from patients； measuring at least one or two levels of RNM expression, In the selected samples of gzma, KLRB1, FoxM1, ccdc90a, CCl4, cpa2, CXCR6, DDO, ech1, fam125b, falg, fg9, gpr15, gzmB, knma1, phf14, tifab, tmem200a, tmigd2 and slc8a3, there are at least three or four high-resolution prediction genes；The RNM expression level detected in the sample was compared with the reference level of each measured heptabromodiphenyl ether, and it was predicted that when the RNM expression level of each measured heptabromodiphenyl ether was higher than the corresponding reference level measured, the patient would be treated. Heptabromodiphenyl ether Requirement 4: a method for the treatment of gastroenteritis, including: (a) measurement of RNM expression level of at least 1, 2, 3 or 4 heptabromodiphenyl ethers selected from gzma, KLRB1, FoxM1, ccd90a, CCl4, cpa2, CXCR6, DDO, ech1,In the biological samples of patients, fam125b, falg, fg9, gpr15, gzmB, knma1, phf14, tifab, tmem200a, tmigd2 and slc8a3； (b) compare the RNM expression level of (a) each heptabromodiphenyl ether measured with the reference level of (a) each heptabromodiphenyl ether measured； (c) determine whether the patients are likely to meet the treatment standards including one treatment； (c) patients a. When the RNM expression level of each heptabromodiphenyl ether measured with (a) is higher than the reference level of each heptabromodiphenyl ether measured, B7 type anti synthetic substance；y (d) administrar la terapia cuando el nivel de expresi n de ARNm de cada HEPG medido en (a) est por encima del respectivo nivel de referencia para cada uno de los HEPG medidos con lo cual se trata el trastorno inflamatorio gastrointestinal Reivindicaci n 41 In biological samples taken from patients, tmigd2 and slc8a3； and (b) instructions
